All epilepsy drugs carry a warning about an increased risk of suicidal behavior, but only certain newer medications could be connected to the hazard, a newly published study suggests.

In a study of 44,300 UK patients who used epilepsy drugs between 1990 and 2005, researchers found an increased risk of suicide only among current users of certain newer medications that have previously been linked to a risk of depression.

Those drugs include topiramate (Topamax), tiagabine (Gabitril), levetiracetam (Keppra) and vigabatrin (Sabril).

The findings were published in the journal Neurology. In 2008, the Food and Drug Administration started requiring all epilepsy drugs to carry a warning about the risk of suicidal behavior.

That requirement came from studying 199 clinical trials testing 11 different epilepsy medications, which found that patients receiving medication had a higher rate of suicidal thoughts and behavior during the study periods than those given a placebo.

Increase your money and finance knowledge from home

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

What are Penny Stocks

The lucrative and dangerous world of penny stocks.

View Course »

Add a Comment

*0 / 3000 Character Maximum